EP1119352A4 - Behandlungsmethode des ocularen oxidativen stresses - Google Patents

Behandlungsmethode des ocularen oxidativen stresses

Info

Publication number
EP1119352A4
EP1119352A4 EP00961334A EP00961334A EP1119352A4 EP 1119352 A4 EP1119352 A4 EP 1119352A4 EP 00961334 A EP00961334 A EP 00961334A EP 00961334 A EP00961334 A EP 00961334A EP 1119352 A4 EP1119352 A4 EP 1119352A4
Authority
EP
European Patent Office
Prior art keywords
treatment
oxidative stress
ocular oxidative
ocular
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00961334A
Other languages
English (en)
French (fr)
Other versions
EP1119352A1 (de
Inventor
John E Repine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Webb-Waring Institute for Biomedical Research
Original Assignee
Webb-Waring Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Webb-Waring Institute for Biomedical Research filed Critical Webb-Waring Institute for Biomedical Research
Publication of EP1119352A1 publication Critical patent/EP1119352A1/de
Publication of EP1119352A4 publication Critical patent/EP1119352A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00961334A 1999-08-09 2000-08-09 Behandlungsmethode des ocularen oxidativen stresses Withdrawn EP1119352A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14796599P 1999-08-09 1999-08-09
US147965P 1999-08-09
PCT/US2000/021784 WO2001024794A1 (en) 1999-08-09 2000-08-09 A method for the treatment of ocular oxidative stress

Publications (2)

Publication Number Publication Date
EP1119352A1 EP1119352A1 (de) 2001-08-01
EP1119352A4 true EP1119352A4 (de) 2004-05-26

Family

ID=22523657

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00961334A Withdrawn EP1119352A4 (de) 1999-08-09 2000-08-09 Behandlungsmethode des ocularen oxidativen stresses

Country Status (4)

Country Link
EP (1) EP1119352A4 (de)
AU (1) AU7330200A (de)
CA (1) CA2350715A1 (de)
WO (1) WO2001024794A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583863A1 (de) * 1992-08-20 1994-02-23 Transcend Therapeutics, Inc. Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese
US5358943A (en) * 1987-12-29 1994-10-25 Clark Abbot F Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
US5510101A (en) * 1992-01-16 1996-04-23 Zambon Group S.P.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249047B (it) * 1991-02-21 1995-02-11 Zambon Spa Composizione farmaceutica per il trattamento della cataratta

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358943A (en) * 1987-12-29 1994-10-25 Clark Abbot F Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
US5510101A (en) * 1992-01-16 1996-04-23 Zambon Group S.P.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
EP0583863A1 (de) * 1992-08-20 1994-02-23 Transcend Therapeutics, Inc. Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, GOHLKE F ET AL: "Acute tubulo-interstitial nephritis and uveitis syndrome (TINU syndrome)", XP002275350, Database accession no. PREV199598556200 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, GARBE EDELTRAUT ET AL: "Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids", XP002275351, Database accession no. PREV199799794523 *
DMW (DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT), vol. 120, no. 21, 1995, pages 753 - 757, ISSN: 0012-0472 *
LANCET (NORTH AMERICAN EDITION), vol. 350, no. 9083, 1997, pages 979 - 982, ISSN: 0099-5355 *
See also references of WO0124794A1 *

Also Published As

Publication number Publication date
AU7330200A (en) 2001-05-10
WO2001024794A1 (en) 2001-04-12
EP1119352A1 (de) 2001-08-01
CA2350715A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
GB2351661B (en) Novel method of treatment
SG86377A1 (en) Method of sterilization
AU2001249881A1 (en) Method of treating the heart
IL145875A0 (en) Novel method of treatment
IL146769A0 (en) Method of sterilizing
HUP0200738A3 (en) Method of the treatment of incontinence
AU7750100A (en) Method for the treatment of obesity
EP1119352A4 (de) Behandlungsmethode des ocularen oxidativen stresses
GB9904765D0 (en) Plant treatment method
GB9930688D0 (en) Novel method of treatment
AU4598400A (en) Method of treatment
AU2382601A (en) Novel method of treatment
ZA987960B (en) Methods for treating ocular diseases
GB9930696D0 (en) Novel method of treatment
GB9915597D0 (en) Method of treatment
TJ99000556A (en) Method of treatment of nevrodermite
GB9903950D0 (en) Method of treatment
GB9929717D0 (en) A novel method for the treatment of dentine hypersensitivity
GB9930690D0 (en) Novel method of treatment
GB9930689D0 (en) Novel method of treatment
GB9930692D0 (en) Novel method of treatment
GB0122638D0 (en) Novel method of treatment
TJ98000539A (en) A method of treatment mange
TJ98000519A (en) A method for the treatment of virus hepatitie
GB9919126D0 (en) Glaucoma treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040408

17Q First examination report despatched

Effective date: 20040716

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041129